Experimental cancer drug DT-9081 trial halted early
NCT ID NCT05582850
First seen May 24, 2026 · Last updated May 24, 2026
Summary
This early-phase study tested a new drug called DT-9081 in 29 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institut Claudius Regaud
Toulouse, France
-
Institut Curie
Paris, France
-
Institut Jules Bordet
Anderlecht, Belgium
-
Université Catholique de Louvain
Leuven, Belgium
Conditions
Explore the condition pages connected to this study.